During a study covering the period from 2006 to 2016, three types of agreements among drug distributors were identified. Among them was the practice of restricting the distribution of drugs on specific days, sharing confidential information about clients, and manipulating product prices.
One of the representatives of the commission responsible for conducting the investigation commented: "These agreements among distributors not only harm competition in the market but may also negatively affect consumers by limiting their access to certain medications or artificially increasing prices."
Moreover, it was revealed that these anti-competitive practices could have a significant impact on the health sector's economy, causing price distortions and affecting the availability of medications for patients.
The competent authorities are evaluating measures to be taken in response to this issue, aiming to ensure free competition and protect consumer interests in the drug distribution market.
